Publication:
Infliximab therapy in behcet's uveitis

dc.contributor.authorAlizadegan, F.
dc.contributor.buuauthorYalçınbayır, O.
dc.contributor.buuauthorGündüz, G. Uçan
dc.contributor.buuauthorPehlivan, Y.
dc.contributor.buuauthorPEHLİVAN, YAVUZ
dc.contributor.buuauthorYALÇINBAYIR, ÖZGÜR
dc.contributor.orcid0000-0002-7311-5277
dc.contributor.orcid0000-0002-5458-1686
dc.contributor.researcheridIYJ-9408-2023
dc.contributor.researcheridAAH-6661-2021
dc.date.accessioned2024-09-12T08:13:06Z
dc.date.available2024-09-12T08:13:06Z
dc.date.issued2022-10-20
dc.description.abstractPurpose. - To evaluate the efficacy of infliximab (IFX) therapy in patients with Behc , et's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).Materials and methods. - This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic char-acteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study.Results. - Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5 +/- 25.9 months. The mean frequency of recurrences during the IMT was 1.47 +/- 0.78 (attacks/year), decreasing to 0.31 +/- 0.40 (attacks/year) with IFX (P < 0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P = 0.026). Partial response to treatment was achieved in 91.4% of cases.Conclusion. - IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.
dc.identifier.doi10.1016/j.jfo.2022.04.009
dc.identifier.endpage1041
dc.identifier.issn0181-5512
dc.identifier.issue9
dc.identifier.startpage1036
dc.identifier.urihttps://doi.org/10.1016/j.jfo.2022.04.009
dc.identifier.urihttps://hdl.handle.net/11452/44629
dc.identifier.volume45
dc.identifier.wos000877684400023
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherMasson Editeur
dc.relation.journalJournal Francais D Ophtalmologie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNecrosis-factor-alpha
dc.subjectRefractory uveoretinitis
dc.subjectFollow-up
dc.subjectDisease
dc.subjectCytokines
dc.subjectInduction
dc.subjectRemission
dc.subjectAnti tumor necrosis factor
dc.subjectBehcet&rsquo
dc.subjectS disease
dc.subjectInfliximab
dc.subjectNoninfectious
dc.subjectUveitis
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectOphthalmology
dc.titleInfliximab therapy in behcet's uveitis
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication0075f2ae-ae8a-4690-bd46-128775e8efac
relation.isAuthorOfPublicatione21cc14e-0a29-42c8-a7a0-93bd3c780b36
relation.isAuthorOfPublication.latestForDiscovery0075f2ae-ae8a-4690-bd46-128775e8efac

Files

Collections